Business Context and Reporting Period
This Form 8-K is a current report filed by MRI Interventions, Inc. (not Clearpoint Neuro, Inc.) on October 3, 2017. The filing documents the results of the Company's Annual Meeting of Stockholders held on the same date. The Company is incorporated in Delaware and is designated as an emerging growth company.
Key Financial Metrics
This filing is a corporate governance report and does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. No financial statements are included in this document.
Material Changes and Voting Results
The filing details the outcomes of three proposals voted on by stockholders:
- Election of Directors: Seven directors were elected to serve until the 2018 annual meeting. All nominees received significant support, with "For" votes ranging from approximately 4.17 million to 4.48 million. Broker non-votes totaled 1,716,322 for each director.
- Ratification of Auditors: Stockholders ratified the appointment of Cherry Bekaert LLP as the independent registered public accounting firm for the year ending December 31, 2017. The vote was 6,304,717 For, 5,605 Against, and 133,493 Abstain.
- Incentive Compensation Plan: Stockholders approved the Second Amended and Restated 2013 Incentive Compensation Plan. The vote was 3,795,904 For, 758,380 Against, and 173,209 Abstain, with 1,716,322 broker non-votes.
Guidance, Outlook, and Disclosures
Under Item 7.01 (Regulation FD Disclosure), the Company posted an updated investor presentation to its website on October 3, 2017. The filing explicitly states that this presentation is not deemed "filed" for purposes of Section 18 of the Exchange Act and is not incorporated by reference into other filings unless specifically referenced. The Company undertakes no obligation to update the information in the presentation.
Investor Verification Checklist
- Verify the correct registrant name is MRI Interventions, Inc., as the input metadata incorrectly referenced Clearpoint Neuro, Inc.
- Review the full text of the Second Amended and Restated 2013 Incentive Compensation Plan (Exhibit 10.1) to understand the specific terms approved by stockholders.
- Consult the 2017 Proxy Statement (filed September 5, 2017) for detailed descriptions of the director nominees and the compensation plan.
- Check the Company's investor relations website for the October 2017 Investor Presentation referenced in Item 7.01, noting that it is not an official SEC filing.